Law360 reported that the U.S. Court of Appeals for the Federal Circuit upheld the PTAB’s decision that UCB Pharma GmbH’s patent covering the drug Toviaz® was correctly upheld in an IPR challenge from Amerigen Pharmaceuticals Ltd.

According to Law360, the appeals court found that the PTAB was correct to find in favor of UCB —​ which licenses the patent to Pfizer Inc. — and hold that Amerigen had not shown that the patent was invalid as obvious.

“We conclude that Amerigen's factual challenges to the board's decision are without merit and that substantial evidence supports the board’s findings," the court said in its decision, according to Law360.